Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase II results show prolonged immune responses with DN24-02 in patients with urothelial cancer

Feb. 10, 2014

TG-01 enters phase IIa trial in operable pancreatic cancer

Feb. 7, 2014

Preliminary phase I results show safety of DC-Ad-GMCAIX treatment in patients with RCC

Feb. 6, 2014

PSMA-ADC treatment leads to CTC and PSA reductions in patients with metastatic CRPC

Feb. 6, 2014

Shionogi initiates phase II study of cancer peptide vaccine in-licensed from OncoTherapy Science

Feb. 6, 2014

XBiotech and EMA agree on phase III registration study for Xilonix

Feb. 3, 2014

Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center licenses anticancer MAb to Novartis

Jan. 31, 2014

Quest PharmaTech to conduct phase II trial of oregovomab combined with Hiltonol

Jan. 30, 2014

Cancer Research UK launches trial of antibody for treatment of lymphoma

Jan. 30, 2014

Novel monoclonal antibodies presented by the University of Texas System

Jan. 30, 2014

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...